Search Legislation

Advanced Search

The Health Protection (Coronavirus, Restrictions) (Self-Isolation) (England) Regulations 2020

Help about what version

What Version

Help about advanced features

Advanced Features

Help about opening options

Opening Options

Status:

Point in time view as at 30/11/2021. This version of this provision has been superseded. Help about Status

Close

Status

You are viewing this legislation item as it stood at a particular point in time. A later version of this or provision, including subsequent changes and effects, supersedes this version.

Note the term provision is used to describe a definable element in a piece of legislation that has legislative effect – such as a Part, Chapter or section.

Changes to legislation:

There are currently no known outstanding effects for the The Health Protection (Coronavirus, Restrictions) (Self-Isolation) (England) Regulations 2020, Section 2B. Help about Changes to Legislation

Close

Changes to Legislation

Revised legislation carried on this site may not be fully up to date. At the current time any known changes or effects made by subsequent legislation have been applied to the text of the legislation you are viewing by the editorial team. Please see ‘Frequently Asked Questions’ for details regarding the timescales for which new effects are identified and recorded on this site.

[F1Requirements on person notified as a close contact of a person who has tested positive for coronavirusE+W

This section has no associated Explanatory Memorandum

2B.—(1) This regulation applies where an adult is notified by a relevant person, other than by means of the NHS Covid 19 smartphone app developed and operated by the Secretary of State, that—

(a)they have had close contact with someone who has tested positive for coronavirus, F2...

F3(b). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

[F4(ba)they have had close contact with a person who has tested positive for coronavirus and that person is suspected of, or confirmed as, having an Omicron variant, or

(c)a child in respect of whom they are a responsible adult has had close contact with a person who has tested positive for coronavirus and that person is suspected of, or confirmed as, having an Omicron variant.]

(2) Where paragraph (1)(a) applies, the person notified must self-isolate for the period of self-isolation unless [F5paragraph (6) applies or]—

(a)they are taking part in coronavirus related research, and

(b)that research cannot be completed if they self-isolate.

F6(3) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

[F7(3A) Where paragraph (1)(ba) applies, the person notified must self-isolate for the period of self-isolation.

(3B) Where paragraph (1)(c) applies, R must secure, so far as reasonably practicable, that the child self-isolates for the period of self-isolation.]

(4) In addition, P [F8, or R where P is a child,] F9... must if, requested by a relevant person, notify that person of the address at which P will remain pursuant to the requirement in regulation 2(1)(a).

(5) If a relevant person notifies P [F10, or R where P is a child,] F11... that a notification referred to in paragraph (1) in respect of P is withdrawn, such notification is deemed never to have been given for the purposes of these Regulations.

[F12(5A) Paragraph (5B) applies where P is an adult and a relevant person notifies P that the person who tested positive for coronavirus with whom P has had close contact does not have, or is no longer suspected of having, an Omicron variant.

(5B) In a case referred to in paragraph (5A), paragraph (1)(a) applies to P from the point at which the notification is received.]

[F13(6) This paragraph applies if—

(a)the person (“NP”) has completed a course of doses of an authorised vaccine, and

(i)that course of doses was administered to NP in the United Kingdom, and

(ii)[F14the relevant day] is more than 14 days after the day on which NP completed that course of doses,

(b)NP has participated, or is participating, in a clinical trial of a vaccine for vaccination against coronavirus carried out in the United Kingdom in accordance with the requirements of the Medicines for Human Use (Clinical Trials) Regulations 2004, or

(c)NP is able to provide evidence that, for clinical reasons, NP should not be vaccinated with any authorised vaccine.

(7) For the purposes of paragraph (6), a person has completed a course of doses if that person has received the complete course of doses specified—

(a)in the summary of product characteristics approved as part of the marketing authorisation for the authorised vaccine, or

(b)in the instructions for usage approved as part of the authorisation by the licensing authority on a temporary basis under regulation 174 (supply in response to spread of pathogenic agents etc) of the Human Medicines Regulations 2012 for the authorised vaccine.

[F15(7A) For the purposes of paragraph (6)(a), “the relevant day” means—

(a)where the person who has tested positive for coronavirus with whom NP has had close contact (“C”) is a member of the same household as NP—

(i)the date which C reported to a relevant person as the date on which symptoms first developed, or

(ii)if C has no symptoms of coronavirus, the day on which C took the test for coronavirus which resulted in a positive result, or

(b)in any other case, the day on which NP had the close contact which resulted in the notification described in paragraph (1).

(7B) For the purposes of paragraph (7), where a person has received a dose of one authorised vaccine and a dose of a different authorised vaccine, that person is deemed to have completed a course of doses of an authorised vaccine.]

(8) In this regulation—

“authorised vaccine” means a medicinal product—

(a)

authorised for supply in the United Kingdom in accordance with a marketing authorisation, or

(b)

authorised by the licensing authority on a temporary basis under regulation 174 of the Human Medicines Regulations 2012,

for vaccination against coronavirus;

“clinical trial” has the meaning given in regulation 2(1) (interpretation) of the Medicines for Human Use (Clinical Trials) Regulations 2004;

“the licensing authority” has the meaning given in regulation 6(2) (the licensing authority and the Ministers) of the Human Medicines Regulations 2012;

“marketing authorisation” has the meaning given in regulation 8(1) (general interpretation) of the Human Medicines Regulations 2012;

“medicinal product” has the meaning given in regulation 2 (medicinal products) of the Human Medicines Regulations 2012.]

[F16(9) For the purposes of paragraph (1)(ba) and (c), a person (“A”) who has tested positive for coronavirus is suspected of, or confirmed as, having an Omicron variant where molecular testing (including PCR tests, genotyping or sequencing) has identified that A is suspected of having, or does have, an Omicron variant.]]

Textual Amendments

Back to top

Options/Help

Print Options

Close

Legislation is available in different versions:

Latest Available (revised):The latest available updated version of the legislation incorporating changes made by subsequent legislation and applied by our editorial team. Changes we have not yet applied to the text, can be found in the ‘Changes to Legislation’ area.

Original (As Enacted or Made): The original version of the legislation as it stood when it was enacted or made. No changes have been applied to the text.

Point in Time: This becomes available after navigating to view revised legislation as it stood at a certain point in time via Advanced Features > Show Timeline of Changes or via a point in time advanced search.

Close

See additional information alongside the content

Geographical Extent: Indicates the geographical area that this provision applies to. For further information see ‘Frequently Asked Questions’.

Show Timeline of Changes: See how this legislation has or could change over time. Turning this feature on will show extra navigation options to go to these specific points in time. Return to the latest available version by using the controls above in the What Version box.

Close

Opening Options

Different options to open legislation in order to view more content on screen at once

Close

Explanatory Memorandum

Explanatory Memorandum sets out a brief statement of the purpose of a Statutory Instrument and provides information about its policy objective and policy implications. They aim to make the Statutory Instrument accessible to readers who are not legally qualified and accompany any Statutory Instrument or Draft Statutory Instrument laid before Parliament from June 2004 onwards.

Close

More Resources

Access essential accompanying documents and information for this legislation item from this tab. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as enacted version that was used for the print copy
  • lists of changes made by and/or affecting this legislation item
  • confers power and blanket amendment details
  • all formats of all associated documents
  • correction slips
  • links to related legislation and further information resources
Close

Timeline of Changes

This timeline shows the different points in time where a change occurred. The dates will coincide with the earliest date on which the change (e.g an insertion, a repeal or a substitution) that was applied came into force. The first date in the timeline will usually be the earliest date when the provision came into force. In some cases the first date is 01/02/1991 (or for Northern Ireland legislation 01/01/2006). This date is our basedate. No versions before this date are available. For further information see the Editorial Practice Guide and Glossary under Help.

Close

More Resources

Use this menu to access essential accompanying documents and information for this legislation item. Dependent on the legislation item being viewed this may include:

  • the original print PDF of the as made version that was used for the print copy
  • correction slips

Click 'View More' or select 'More Resources' tab for additional information including:

  • lists of changes made by and/or affecting this legislation item
  • confers power and blanket amendment details
  • all formats of all associated documents
  • links to related legislation and further information resources